Related Experiment Video
Updated: Jul 20, 2026
Exploring the Arginine Methylome by Nuclear Magnetic Resonance Spectroscopy
Published on: December 16, 2021
HPLC analysis of ADMA and other methylated L-arginine analogs in biological fluids
1Metabolic Laboratory, Department of Clinical Chemistry, VU University Medical Center, Amsterdam, The Netherlands. t.teerlink@vumc.nl
Abstract:
Post-translational methylation of arginine residues in proteins leads to generation of N(G)-monomethylarginine (MMA) and both symmetric and asymmetric dimethylarginine (SDMA and ADMA), that are released into the cytosol upon proteolysis. Both MMA and ADMA are inhibitors of nitric oxide synthase and especially elevated levels of ADMA are associated with endothelial dysfunction and cardiovascular disease. Plasma concentrations of ADMA and SDMA are very low, typically between 0.3 and 0.8 microM, making their quantification by HPLC an analytical challenge. Sample preparation usually involves a cleanup step by solid-phase extraction on cation-exchange columns followed by derivatization of amino acids into fluorescent adducts. Because ADMA and SDMA concentrations in healthy subjects show a very narrow distribution, with a between-subject variability of 13% for ADMA and 19% for SDMA, very low imprecision is an essential assay feature. Procedures for sample cleanup, derivatization, and chromatographic separation of arginine and its methylated analogs are the main topics of this review. In addition, important aspects of method validation, pre-analytical factors, and reference values are discussed.
Insights
Quantifying N(G)-monomethylarginine (MMA), symmetric dimethylarginine (SDMA), and asymmetric dimethylarginine (ADMA) is crucial for cardiovascular health. This review details analytical methods for these nitric oxide synthase inhibitors in plasma.
Area of Science:
- Biochemistry
- Analytical Chemistry
- Cardiovascular Research
Background:
- Post-translational methylation of arginine produces MMA, SDMA, and ADMA, which are released during proteolysis.
- ADMA and SDMA are low in plasma (0.3-0.8 microM) and linked to endothelial dysfunction and cardiovascular disease.
- Accurate quantification is challenging due to low concentrations and narrow distribution in healthy individuals.
Purpose of the Study:
- To review methods for quantifying arginine methylation products (MMA, SDMA, ADMA).
- To discuss challenges and essential features for accurate plasma analysis.
- To cover sample preparation, derivatization, chromatographic separation, validation, and reference values.
Main Methods:
- Solid-phase extraction on cation-exchange columns for sample cleanup.
- Derivatization of amino acids into fluorescent adducts.
- High-performance liquid chromatography (HPLC) for separation and quantification.
Main Results:
- Established procedures for sample cleanup, derivatization, and chromatographic separation are critical.
- Low imprecision is essential due to narrow inter-individual variability (13% for ADMA, 19% for SDMA).
- Method validation and pre-analytical factors significantly impact assay reliability.
Conclusions:
- Accurate quantification of MMA, SDMA, and ADMA requires optimized analytical procedures.
- Understanding these arginine metabolites is vital for diagnosing and managing cardiovascular conditions.
- This review provides a comprehensive guide for researchers and clinicians in the field.
